Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts

被引:143
作者
Hess, P
Pihan, G
Sawyers, CL
Flavell, RA
Davis, RJ
机构
[1] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA
[2] Univ Massachusetts, Sch Med, Program Mol Biol, Worcester, MA 01605 USA
[3] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA
[4] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90024 USA
[5] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[6] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA
[7] Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/ng946
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The c-Jun NH2-terminal kinase (JNK) is implicated in the apoptotic response of cells exposed to stress(1), but the JNK signal transduction pathway may not act exclusively in apoptosis(1). In some studies of tumor cells, JNK has been implicated in signaling cell survival(1). The possibility that JNK might mediate a survival signal in tumor cells is consistent with the observation that it is activated in response to some oncogenes, such as the leukemogenic oncogene BCR-ABL, which is created by a reciprocal translocation between human chromosomes 9 and 22 (ref. 2). The BCR-ABL protein activates the JNK signaling pathway in hematopoietic cells and increases transcriptional activity mediated by the transcription factor AP1 (ref. 3). Also, inhibition of c-Jun or JNK prevents BCR-ABL-induced cell transformation in vitro(3,4). Although this implicates the JNK signaling pathway in transformation by BCR-ABL, the possible role of JNK in this process is unclear. We find that disruption of the JNK ortholog Mapk8 (also known as Jnk1) in mice causes defective transformation of pre-B cells by BCR-ABL in vitro and in vivo. The Jnk1 protein is required for the survival of the transformed cells in the absence of stromal support. Failure to survive is associated with decreased expression of Bcl2, and the effect of Jnk1 deficiency can be rescued by transgenic expression of Bcl2. Our results show that Jnk1 signals cell survival in transformed B lymphoblasts and suggest that it may contribute to the pathogenesis of some proliferative diseases.
引用
收藏
页码:201 / 205
页数:5
相关论文
共 29 条
[21]   TUMORIGENIC ACTIVITY OF THE BCR-ABL ONCOGENES IS MEDIATED BY BCL2 [J].
SANCHEZGARCIA, I ;
GRUTZ, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) :5287-5291
[22]   Chronic myeloid leukemia [J].
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (17) :1330-1340
[23]  
Shuai K, 1996, ONCOGENE, V13, P247
[24]   Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway [J].
Skorski, T ;
Bellacosa, A ;
NieborowskaSkorska, M ;
Majewski, M ;
Martinez, R ;
Choi, JK ;
Trotta, R ;
Wlodarski, P ;
Perrotti, D ;
Chan, TO ;
Wasik, MA ;
Tsichlis, PN ;
Calabretta, B .
EMBO JOURNAL, 1997, 16 (20) :6151-6161
[25]   ENFORCED BCL2 EXPRESSION IN B-LYMPHOID CELLS PROLONGS ANTIBODY-RESPONSES AND ELICITS AUTOIMMUNE-DISEASE [J].
STRASSER, A ;
WHITTINGHAM, S ;
VAUX, DL ;
BATH, ML ;
ADAMS, JM ;
CORY, S ;
HARRIS, AW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8661-8665
[26]   MURINE B-CELL LYMPHOPOIESIS IN LONG-TERM CULTURE [J].
WHITLOCK, CA ;
ROBERTSON, D ;
WITTE, ON .
JOURNAL OF IMMUNOLOGICAL METHODS, 1984, 67 (02) :353-369
[27]  
Wilson BE, 1996, MOL CELL BIOL, V16, P5546
[28]   Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia [J].
Zhang, XW ;
Ren, RB .
BLOOD, 1998, 92 (10) :3829-3840
[29]   Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization [J].
Zindy, F ;
Eischen, CM ;
Randle, DH ;
Kamijo, T ;
Cleveland, JL ;
Sherr, CJ ;
Roussel, MF .
GENES & DEVELOPMENT, 1998, 12 (15) :2424-2433